BLRX
OtherBioline Rx Ltd
Live · NASDAQ · May 9, Close
What's Moving BLRX Today?
No stock-specific AI insight has been generated for BLRX yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
BLRX News
20 articles- BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)Yahoo Finance·Apr 28, 2026
- Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in GlioblastomaYahoo Finance·Apr 8, 2026
- BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)Yahoo Finance·Mar 26, 2026
- BioLine Rx Ltd (BLRX) Full Year 2025 Earnings Call Highlights: Navigating Challenges and ...Yahoo Finance·Mar 26, 2026
- BLRX: Full Year 2025 ResultsYahoo Finance·Mar 23, 2026
- BioLineRx Reports 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 23, 2026
- BioLineRx to Report 2025 Annual Results on March 23, 2026Yahoo Finance·Mar 16, 2026
- BioLine Rx Ltd (BLRX) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...Yahoo Finance·Nov 29, 2025
- BLRX: Stem Cell Mobilization Presentation at ASHYahoo Finance·Nov 25, 2025
- BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Nov 24, 2025
- BioLineRx to Report Third Quarter 2025 Results on November 24, 2025Yahoo Finance·Nov 18, 2025
- BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer TypesYahoo Finance·Nov 17, 2025
- BLRX: A Venture into GBMYahoo Finance·Sep 30, 2025
- BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other CancersYahoo Finance·Sep 29, 2025
- BLRX: ASCO Poster & AbstractYahoo Finance·Aug 15, 2025
- BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Aug 14, 2025
- BioLineRx to Report Second Quarter 2025 Results on August 14, 2025Yahoo Finance·Aug 7, 2025
- H.C. Wainwright Reaffirms Buy on BioLineRx Ltd. (BLRX) After ASCO 2025Yahoo Finance·Jul 3, 2025
- BioLineRx upgraded to Buy from Hold at JonesResearchYahoo Finance·May 31, 2025
- Why Is Nano-Cap BioLineRx Stock Surging On Friday?Yahoo Finance·May 30, 2025
All 20 articles loaded
Price Data
Fundamentals
Trading
About Bioline Rx Ltd
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.